PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28662409-6 2017 The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-beta signaling and production of pro-fibrotic cytokines, including TNF-alpha, IL-1beta. Bleomycin 157-166 tumor necrosis factor Mus musculus 272-281 28743499-6 2017 Furthermore, bleomycin upregulated EphA2, EphrinA1, PI3K 110gamma, Akt, IL-6 and TNF-alpha. Bleomycin 13-22 tumor necrosis factor Mus musculus 81-90 28743499-8 2017 In addition, ATRA suppressed IL-6 and TNF-alpha production induced by bleomycin-induced injury. Bleomycin 70-79 tumor necrosis factor Mus musculus 38-47 28678919-6 2017 As a result, cell viability was significantly decreased, as well as apoptosis and the expression of IL-1 and TNF-alpha were remarkably increased after 50 and 100 mug/mL of bleomycin administration. Bleomycin 172-181 tumor necrosis factor Mus musculus 109-118 27895584-10 2016 In addition, iPS cell administration remarkably suppressed BLM-induced up-regulation of pulmonary inflammatory mediators, including tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and prostaglandin E2. Bleomycin 59-62 tumor necrosis factor Mus musculus 132-159 25551570-8 2014 Instillation of both bleomycin and Ad vectors increased expression levels of TNFalpha and IL-1beta but not IL-10. Bleomycin 21-30 tumor necrosis factor Mus musculus 77-85 24885478-5 2014 Compared with littermate wild-type (WT) mice, TGF-beta1(wt) Tg mice had over twofold-higher levels of latent TGF-beta1 in both plasma and lung tissue, and were protected from bleomycin-induced pulmonary inflammation, such as up-regulation of IL-1beta, TNF-alpha, and macrophage chemotactic protein-1, and infiltration of CD3(+) T cells and F4/80(+) macrophages. Bleomycin 175-184 tumor necrosis factor Mus musculus 252-261 25026360-12 2014 Bleomycin led to an increase in TNF-alpha and interleukin-6 (IL-6) (7.9 and 11.8 pg/ml). Bleomycin 0-9 tumor necrosis factor Mus musculus 32-41 24886817-6 2014 Bleomycin exposure induced expression of MDA, IKKalpha, phosphorylated IKKalpha (p-IKKalpha), NF-kappaB P65, TNF-alpha and IL-1beta, and reduced I-kappaB expression in mice lung tissue or in BALF. Bleomycin 0-9 tumor necrosis factor Mus musculus 109-118 24998650-8 2014 There was a tendency that serum TGF-beta1 and TNF-alpha levels increased in bleomycin-treated mice, but no significant difference was found between wild type and AQP4-/- mice. Bleomycin 76-85 tumor necrosis factor Mus musculus 46-55 24325577-7 2014 In contrast, fibrosis and alternative macrophage programming were prolonged in bleomycin-instilled TNF-alpha(-/-) mice. Bleomycin 79-88 tumor necrosis factor Mus musculus 99-108 24339053-3 2013 In the present study, we attempted the local administration of tumor necrosis factor alpha antisense oligonucleotide and evaluated the treatment effects on pulmonary fibrosis in a bleomycin-induced pulmonary fibrosis mouse model. Bleomycin 180-189 tumor necrosis factor Mus musculus 63-90 22322299-2 2012 Transgenic mice overexpressing TNF-alpha in type II alveolar epithelial cells under the control of the surfactant protein (SP)-C promoter develop pulmonary inflammation and emphysema but are resistant to induction of fibrosis by administration of bleomycin or transforming growth factor-beta. Bleomycin 247-256 tumor necrosis factor Mus musculus 31-40 20302663-12 2010 CONCLUSIONS: Iloprost prevents bleomycin-induced pulmonary fibrosis, possibly by upregulating antifibrotic mediators (IFNgamma and CXCL10) and downregulating pro-inflammatory and pro-fibrotic cytokines (TNFalpha, IL-6, and TGFbeta1). Bleomycin 31-40 tumor necrosis factor Mus musculus 203-211 19909737-6 2010 Enzyme-linked immunosorbent assay and radio-immunity assay showed that treatment with neferine alleviated bleomycin-induced increase of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and endothelin-1 in plasma or in tissue. Bleomycin 106-115 tumor necrosis factor Mus musculus 171-204 19758314-0 2010 Tumor necrosis factor-alpha processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma. Bleomycin 79-88 tumor necrosis factor Mus musculus 0-27 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Bleomycin 235-244 tumor necrosis factor Mus musculus 96-123 19080365-7 2008 Simultaneously, the accumulation of neutrophils and lymphocytes and the increased production of tumor necrosis factor-alpha (TNF-alpha) in bronchial alveolar lavage fluid were inhibited by simvastatin in early inflammatory phase after bleomycin infusion. Bleomycin 235-244 tumor necrosis factor Mus musculus 125-134 17673693-8 2007 In functional studies performed in the bleomycin-induced lung fibrosis model, the level of expression of these two genes was closely correlated with specific early events associated with lung fibrosis, namely activation of polymorphonuclear neutrophil-derived serine proteases and tumor necrosis factor-alpha-dependent inflammatory syndrome. Bleomycin 39-48 tumor necrosis factor Mus musculus 281-308 17569779-5 2007 Additive effects of CCL18 overexpression and bleomycin injury were observed on pulmonary inflammation, particularly on T-cell infiltration, and increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-2, and MMP-9. Bleomycin 45-54 tumor necrosis factor Mus musculus 164-191 17880775-4 2007 An increase in immunoreactivity to nitrotyrosine, iNOS, TNF-alpha and IL-1beta was also observed in the lungs of BLM-treated mice. Bleomycin 113-116 tumor necrosis factor Mus musculus 56-65 17880775-5 2007 In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-alpha and IL-1beta and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining. Bleomycin 31-34 tumor necrosis factor Mus musculus 230-239 17569781-7 2007 Therefore, MSCs protect lung tissue from BLM-induced injury by blocking TNF-alpha and IL-1, two fundamental proinflammatory cytokines in lung. Bleomycin 41-44 tumor necrosis factor Mus musculus 72-81 17135359-5 2007 When compared with bleomycin-treated GITR+/+ mice, bleomycin-treated GITR-/- mice exhibited a reduced degree of i) lung infiltration with polymorphonuclear neutrophils (MPO activity); ii) edema formation; iii) histological evidence of lung injury; iv) TNF-alpha and interleukin (IL)-1beta production; v) nitrotyrosine formation; and vi) NF-kappaB activation. Bleomycin 51-60 tumor necrosis factor Mus musculus 252-261 16317386-4 2005 An increase of immunoreactivity to poly-ADP-ribose, TNF-alpha, and IL-1 beta, as well as a significant loss of body weight and mortality was observed in the lung of bleomycin-treated PPAR-alpha WT mice. Bleomycin 165-174 tumor necrosis factor Mus musculus 52-61 15541506-8 2004 This effect was associated with significant inhibition of bleomycin-induced tumor necrosis factor alpha and transforming growth factor beta expression in lung homogenates. Bleomycin 58-67 tumor necrosis factor Mus musculus 76-103 15337842-3 2004 Indeed, we have good evidence, not yet published, that tetrathiomolybdate inhibits pulmonary levels of transforming growth factor-beta and tumor necrosis factor-alpha expression in these bleomycin experiments. Bleomycin 187-196 tumor necrosis factor Mus musculus 139-166 12816730-0 2003 Overexpression of tumor necrosis factor-alpha diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-beta. Bleomycin 87-96 tumor necrosis factor Mus musculus 18-45 12816730-4 2003 In this study we evaluated whether TNF-alpha overexpression altered the development of pulmonary fibrosis due to bleomycin or transforming growth factor-beta (TGF-beta). Bleomycin 113-122 tumor necrosis factor Mus musculus 35-44 12816730-8 2003 TNF-alpha transgenic mice tolerated bleomycin or AdTGF-beta, whereas the transgene-negative littermates demonstrated severe pulmonary fibrosis after either agent. Bleomycin 36-45 tumor necrosis factor Mus musculus 0-9 12777247-10 2003 Treatment of lung fibroblasts with tumor necrosis factor-alpha, which is produced early in the bleomycin model, induced SRFDelta5 expression and SRF/SRFDelta5 cytoplasmic accumulation, whereas addition of transforming growth factor-beta1 caused SRF/SRFDelta5 nuclear translocation followed by SM alpha-actin synthesis. Bleomycin 95-104 tumor necrosis factor Mus musculus 35-62 12496444-0 2003 Repression of bleomycin-induced pneumopathy by TNF. Bleomycin 14-23 tumor necrosis factor Mus musculus 47-50 12496444-7 2003 Contrary to previous reports that showed that TNF was a central mediator of pulmonary inflammation, we have demonstrated that TNF is essential for repressing pulmonary inflammation in bleomycin-induced pneumopathy. Bleomycin 184-193 tumor necrosis factor Mus musculus 126-129 12003776-2 2002 Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c). Bleomycin 0-9 tumor necrosis factor Mus musculus 62-89 12003776-2 2002 Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c). Bleomycin 0-9 tumor necrosis factor Mus musculus 91-94 12003776-2 2002 Bleomycin-induced lung injury in mice is mediated by enhanced tumor necrosis factor-alpha (TNF) expression in the lung, which determines the murine strain sensitivity to bleomycin, and murine strains are sensitive (C57BL/6) or resistant (BALB/c). Bleomycin 170-179 tumor necrosis factor Mus musculus 91-94 12003776-4 2002 Bleomycin treatment induced activation of nuclear factor (NF)-kappaB and activator protein (AP)-1 and enhanced collagen and TNF mRNA expression in the lung of C57BL/6 but not in BALB/c mice. Bleomycin 0-9 tumor necrosis factor Mus musculus 124-127 10600896-1 1999 Bleomycin (BLM) induces lung injury and fibrosis in the murine lung and enhances tumor necrosis factor (TNF)-alpha and collagen mRNA expression in the murine lung. Bleomycin 0-9 tumor necrosis factor Mus musculus 81-114 10600896-1 1999 Bleomycin (BLM) induces lung injury and fibrosis in the murine lung and enhances tumor necrosis factor (TNF)-alpha and collagen mRNA expression in the murine lung. Bleomycin 11-14 tumor necrosis factor Mus musculus 81-114 10410269-13 1999 CONCLUSION: These results suggest that bleomycin, as well as IL-1 beta and TNF-alpha, induce NO release from mononuclear cells, and that these cytokines furthermore stimulate fibroblasts to produce NO, which raises the possibility of the involvement of NO in the development of tissue fibrosis induced by bleomycin. Bleomycin 305-314 tumor necrosis factor Mus musculus 75-84 10101016-10 1999 Even though silica and bleomycin induced increases in TNF in the TNFR Ko mice, the mice were protected from the fibrogenic effects of these agents. Bleomycin 23-32 tumor necrosis factor Mus musculus 54-57 10088601-8 1999 Analysis of selected cytokines 1 day after initiation of BLM-induced pulmonary fibrosis indicated that the levels of TNF-alpha and IFN-gamma appeared to segregate with fibrosis in both the SCID and wild-type mice. Bleomycin 57-60 tumor necrosis factor Mus musculus 117-126 9843859-0 1998 Alveolar macrophage apoptosis and TNF-alpha, but not p53, expression correlate with murine response to bleomycin. Bleomycin 103-112 tumor necrosis factor Mus musculus 34-43 11480082-1 1998 OBJECTIVE: mRNA for tumour necrosis factor-alpha(TNF-alpha) and procollagen I [pro alpha 1(I)] and III (pro alpha 1(III) was measured in bleomycin treated mice to evaluate their roles in pulmonary fibrosis. Bleomycin 137-146 tumor necrosis factor Mus musculus 49-58 9839161-0 1998 Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice. Bleomycin 56-65 tumor necrosis factor Mus musculus 39-42 9839161-16 1998 Furthermore, in addition to the release of the TNF ligand, it appears that the presence of TNF receptors is necessary for the development of BLM-induced lung injury, and signaling through these receptors may contribute to the regulation of the TGF-beta 1 mRNA expression observed in response to bleomycin. Bleomycin 295-304 tumor necrosis factor Mus musculus 91-94 9766634-0 1998 TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. Bleomycin 46-55 tumor necrosis factor Mus musculus 0-3 9766634-4 1998 In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice. Bleomycin 62-71 tumor necrosis factor Mus musculus 73-94 9766634-4 1998 In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice. Bleomycin 62-71 tumor necrosis factor Mus musculus 96-99 9766634-4 1998 In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice. Bleomycin 194-203 tumor necrosis factor Mus musculus 73-94 9766634-4 1998 In this report, two mediators of the inflammatory response to bleomycin, tumor necrosis factor (TNF) and interleukin-6 (IL-6), were evaluated as putative stimuli for MIP-1alpha expression after bleomycin challenge in CBA/J mice. Bleomycin 194-203 tumor necrosis factor Mus musculus 96-99 9766634-5 1998 Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression. Bleomycin 120-129 tumor necrosis factor Mus musculus 29-32 9766634-5 1998 Elevated levels of bioactive TNF and IL-6 were detected in bronchoalveolar lavage (BAL) fluid and lung homogenates from bleomycin-treated CBA/J mice at time points post-bleomycin challenge, which precede MIP-1alpha protein expression. Bleomycin 169-178 tumor necrosis factor Mus musculus 29-32 9766634-6 1998 Treatment of bleomycin-challenged mice with soluble TNF receptor (sTNFr) or anti-IL-6 antibodies significantly decreased MIP-1alpha protein expression in the lungs. Bleomycin 13-22 tumor necrosis factor Mus musculus 52-55 9766634-8 1998 Finally, leukocytes recovered from the BAL fluid of bleomycin-challenged mice secreted higher levels of MIP-1alpha protein, compared to controls, when treated with TNF alone. Bleomycin 52-61 tumor necrosis factor Mus musculus 164-167 9766634-9 1998 Based on the data presented here, we propose that TNF and IL-6 are part of a cytokine network that modulates MIP-1alpha protein expression in the profibrotic inflammatory lesion during the response to intratracheal bleomycin challenge. Bleomycin 215-224 tumor necrosis factor Mus musculus 50-53 9341282-6 1997 Levels of promotor cytokines, such as TNF alpha, TGF beta, INF gamma, and IL-2, were significantly higher in lung tissue from the bleomycin group. Bleomycin 130-139 tumor necrosis factor Mus musculus 38-47 9177462-0 1997 Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Bleomycin 53-62 tumor necrosis factor Mus musculus 79-88 9166104-7 1997 Bleomycin injections increased collagen deposition, as evaluated by the lung hydroxyproline content, more markedly in wild type, than in delta TNF/LT alpha, mice. Bleomycin 0-9 tumor necrosis factor Mus musculus 143-146 7528044-6 1994 In addition, several treatments known to decrease bleomycin induced collagen deposition and synthesis, namely administration of antibodies against CD11a, CD11b, TNF-alpha and IL-1ra, also decreased platelet trapping. Bleomycin 50-59 tumor necrosis factor Mus musculus 161-170 1374023-3 1992 Significant increases in tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) mRNA were found in lungs of bleomycin-treated responder CBA mice but not in nonresponder BALB/c mice. Bleomycin 140-149 tumor necrosis factor Mus musculus 25-52 1374023-3 1992 Significant increases in tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) mRNA were found in lungs of bleomycin-treated responder CBA mice but not in nonresponder BALB/c mice. Bleomycin 140-149 tumor necrosis factor Mus musculus 54-63 1716490-1 1990 A major role of TNF in pulmonary fibrosis is supported by the following evidences obtained from pulmonary fibrosis induced in mice by bleomycin or silica particles; 1) these diseases are associated with a marked and lasting increase of the TNF mRNA within the lung, 2) they can be prevented by a treatment with anti TNF antibody or aggravated by a perfusion of mouse recombinant TNF, 3) an infusion of TNF-alpha can reproduce the alterations observed during pulmonary fibrosis such as growth of fibroblasts, collagen deposition, cell necrosis. Bleomycin 134-143 tumor necrosis factor Mus musculus 16-19 34142927-5 2021 RESULTS: We found that bleomycin-induced increase in inflammatory cytokines interleukin (IL)-beta1, tumor necrosis factor (TNF)-alpha, monocyte chemotactic protein (MCP)-1, and inflammatory lesions in lung tissue in the early stage of the model. Bleomycin 23-32 tumor necrosis factor Mus musculus 100-133 35548340-0 2022 An Herbal Product Alleviates Bleomycin-Induced Pulmonary Fibrosis in Mice via Regulating NF-kappaB/TNF-alpha Signaling in Macrophages. Bleomycin 29-38 tumor necrosis factor Mus musculus 99-108 35548340-15 2022 Conclusion: Fuzheng Huayu formula has a good effect against pulmonary fibrosis induced by bleomycin in mice, whose action mechanism was associated with down-regulation of NF-kappaB/TNF-alpha signaling pathway in pro-inflammatory macrophages. Bleomycin 90-99 tumor necrosis factor Mus musculus 181-190 2475571-0 1989 Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. Bleomycin 52-61 tumor necrosis factor Mus musculus 0-21 2475571-0 1989 Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. Bleomycin 52-61 tumor necrosis factor Mus musculus 22-31 2475571-1 1989 The role of TNF-alpha/cachectin in the pneumopathy elicited by bleomycin has been investigated. Bleomycin 63-72 tumor necrosis factor Mus musculus 12-21 2475571-1 1989 The role of TNF-alpha/cachectin in the pneumopathy elicited by bleomycin has been investigated. Bleomycin 63-72 tumor necrosis factor Mus musculus 22-31 2475571-2 1989 After a single intratracheal bleomycin instillation, an increase of the lung TNF-alpha mRNA level was evident, from days 5 to 15, as shown by Northern gel analysis of whole lung RNA. Bleomycin 29-38 tumor necrosis factor Mus musculus 77-86 2475571-4 1989 In mice passively immunized with rabbit anti-mouse TNF-alpha IgG, the bleomycin-induced collagen deposition, evaluated by the total lung hydroxyproline assay on day 15, was prevented. Bleomycin 70-79 tumor necrosis factor Mus musculus 51-60 2475571-5 1989 Depletion of the CD4 and CD8 T lymphocytes by an in vivo treatment with mAb prevented the bleomycin-induced increase of TNF mRNA level and fibrosis. Bleomycin 90-99 tumor necrosis factor Mus musculus 120-123 2475571-6 1989 After an administration of bleomycin in continuous intraperitoneal perfusion, the diffuse alveolar damage observed by light and electron microscopy was almost completely prevented by anti-TNF antibody. Bleomycin 27-36 tumor necrosis factor Mus musculus 188-191 2475571-7 1989 These results indicate that in response to bleomycin, the T lymphocytes induce, by an undefined mechanism, an increase of the pulmonary TNF production, which leads to alveolar damage, growth of fibroblast, and collagen deposition. Bleomycin 43-52 tumor necrosis factor Mus musculus 136-139 2448255-4 1987 Cytotoxic antitumor agents of 5-fluorouracil (5-FU), cyclophosphamide (CY) and bleomycin (BLM) suppressed TNF production in mice primed with CP and challenged with LPS. Bleomycin 79-88 tumor necrosis factor Mus musculus 106-109 33647319-4 2021 Herein, we investigated the role of TNFalpha in macrophage responses to bleomycin. Bleomycin 72-81 tumor necrosis factor Mus musculus 36-44 33647319-12 2021 Conversely, it reduced the abundance of mature proinflammatory (Ly6C+) IM in the tissue at 7 d and immature pro-fibrotic IM at 21 d. Taken together, these data suggest that TNFalpha inhibition has beneficial effects in bleomycin induced injury, restoring epithelial function and reducing numbers of profibrotic IM and the extent of pulmonary fibrosis. Bleomycin 219-228 tumor necrosis factor Mus musculus 173-181 31724341-9 2019 Although the TNF-alpha level in BAL of bleomycin-treated mice was reduced by dexamethasone, the neutrophil infiltration remained unchanged. Bleomycin 39-48 tumor necrosis factor Mus musculus 13-22